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Clinical PerspectiveWhat Is New?Combining fibrinolytic therapy with immediate transfer for percutaneous coronary intervention (PCI) has been proposed as a management strategy for ST‐segment--elevation myocardial infarction at centers without PCI capability; this approach is termed facilitated PCI when fibrinolytic to PCI time interval is shorter (\<2 hours) and a pharmacoinvasive approach when this interval is longer (2--24 hours).To date no published trials of have directly compared a pharmacoinvasive approach and facilitated PCI for treatment of ST‐segment--elevation myocardial infarction.We performed a multivariate network meta‐analysis comparing 4 main strategies for treating ST‐segment--elevation myocardial infarction: fibrinolytic therapy, primary PCI, a pharmacoinvasive approach, and facilitated PCI.What Are the Clinical Implications?Primary PCI is the preferred treatment for ST‐segment--elevation myocardial infarction.The key finding of this study is that, in settings where timely primary PCI is not available, a pharmacoinvasive approach is safer and more effective than facilitated PCI or fibrinolytic therapy alone.

 {#jah35065-sec-0008}

See Editorial by Mentias and Girotra

Primary percutaneous coronary intervention (PCI), when performed in a timely manner, is preferred to fibrinolytic therapy for reperfusion therapy during ST‐segment--elevation myocardial infarction (STEMI).[1](#jah35065-bib-0001){ref-type="ref"} However, logistical barriers limit the availability of primary PCI for most patients worldwide. In such situations, administering fibrinolytic therapy remains the customary approach, although this strategy is associated with higher rates of nonfatal reinfarction and worse mortality relative to primary PCI.[2](#jah35065-bib-0002){ref-type="ref"} A more recent development has been the use of fibrinolysis followed by routine transfer for early invasive therapy with coronary angiography and possible PCI. This last strategy potentially leverages the strengths of both approaches by combining the speed and ease of fibrinolytic therapy administration with the reliability and durability of PCI but has been studied to a more limited extent.

Thus, understanding the ideal approach to reperfusion therapy is complicated by a confusing landscape of clinical trials that have compared many but not all of these strategies head‐to‐head. For example, 2 different study designs have evaluated the combination of fibrinolysis with routine early invasive therapy: facilitated PCI and a pharmacoinvasive approach. The key distinction between these 2 designs relates to the time interval between the administration of fibrinolytics and performing PCI. The term *facilitated PCI* has been used when the time interval between fibrinolysis and PCI is shorter (eg, \<2 hours), whereas the term *pharmacoinvasive approach* has implied an intentionally longer fibrinolysis to PCI interval (eg, 2--24 hours). Multiple trials comparing facilitated PCI with primary PCI have consistently found facilitated PCI to be inferior.[3](#jah35065-bib-0003){ref-type="ref"}, [4](#jah35065-bib-0004){ref-type="ref"}, [5](#jah35065-bib-0005){ref-type="ref"}, [6](#jah35065-bib-0006){ref-type="ref"}, [7](#jah35065-bib-0007){ref-type="ref"} In contrast, trials have also consistently demonstrated that the pharmacoinvasive approach is superior to fibrinolytic therapy,[8](#jah35065-bib-0008){ref-type="ref"}, [9](#jah35065-bib-0009){ref-type="ref"}, [10](#jah35065-bib-0010){ref-type="ref"}, [11](#jah35065-bib-0011){ref-type="ref"}, [12](#jah35065-bib-0012){ref-type="ref"}, [13](#jah35065-bib-0013){ref-type="ref"} and multiple studies suggest equivalence to primary PCI when substantial delays are likely.[8](#jah35065-bib-0008){ref-type="ref"}, [14](#jah35065-bib-0014){ref-type="ref"}, [15](#jah35065-bib-0015){ref-type="ref"}, [16](#jah35065-bib-0016){ref-type="ref"} Importantly, no published trials to date have directly compared facilitated PCI with a pharmacoinvasive approach in patients who lack timely access to primary PCI.

As primary PCI is unavailable for a large proportion of the world\'s population, understanding the relative efficacy and safety of alternative reperfusion strategies is necessary for optimizing care for STEMI, which remains a leading cause of death and disability worldwide. Accordingly, we systematically reviewed the published literature and performed a multivariate network meta‐analysis of randomized controlled trials for treatment of STEMI to summarize and compare various strategies for treatment, including primary PCI, fibrinolytic therapy, and facilitated PCI, and a pharmacoinvasive approach.

Methods {#jah35065-sec-0009}
=======

Data Sources and Search Strategy {#jah35065-sec-0010}
--------------------------------

We gathered data from randomized controlled trials of patients with STEMI, presenting within 12 hours of symptom onset, in which any of the following treatments were compared: primary PCI, fibrinolytic therapy, and fibrinolysis followed by routine early (ie, within 24 hours) invasive therapy.

We searched MEDLINE, Embase, and the Cochrane Register of Controlled Trials, from January 1, 1999, to March 20, 2019, using the following key words: "primary angioplasty," "primary percutaneous coronary intervention," "facilitated angioplasty," "facilitated percutaneous coronary intervention," "pharmacoinvasive," "acute myocardial infarction," "ST elevation myocardial infarction," and "ST‐segment--elevation myocardial infarction." We restricted our search to studies following 1999 to focus on those trials that used contemporary management strategies for PCI. We excluded trials that did not routinely use stenting during PCI (use of stents in \<50% of coronary interventions) and those without follow‐up beyond hospital discharge.

We only included reports published in English. We performed our search on March 20, 2019, and identified 62 reports that were reviewed by 2 independent readers (R.F., T.I.J.), with any discrepancies resolved by a third reviewer (B.K.N.).

Data Extraction and Definition of the Reperfusion Strategies {#jah35065-sec-0011}
------------------------------------------------------------

We extracted data regarding study design, inclusion and exclusion criteria, clinical short‐term outcomes, number of patients enrolled, and time delay intervals. The primary clinical end points we abstracted were death, nonfatal reinfarction, stroke, and major bleeding at 30 to 90 days. In all cases, we used the definitions utilized within the individual trials to define these outcomes. These definitions as well as details of protocols for each trial are outlined in Table [S1](#jah35065-sup-0001){ref-type="supplementary-material"}.

We defined primary PCI as immediate PCI without prior administration of fibrinolytics. For our primary analysis, in accordance with time thresholds discussed in the 2017 European Society of Cardiology Guidelines for STEMI management, we categorized routine early PCI after fibrinolysis as facilitated PCI when the average time interval between administration of fibrinolytics and PCI was \<2 hours and as a pharmacoinvasive approach when this interval was ≥2 hours. We did not consider pretreatment of STEMI before PCI with glycoprotein IIb/IIIa receptor inhibitors without fibrinolysis as either facilitated PCI or a pharmacoinvasive approach.

Statistical Analysis {#jah35065-sec-0012}
--------------------

We used multivariate network meta‐analysis, as described by White and colleagues,[17](#jah35065-bib-0017){ref-type="ref"}, [18](#jah35065-bib-0018){ref-type="ref"}, [19](#jah35065-bib-0019){ref-type="ref"} to compare treatment strategies. This method involves the simultaneous analysis of both direct and indirect comparisons among multiple treatment strategies and across multiple studies, thus allowing for competing interventions (ie, reperfusion strategies in this case) to be ranked based on the likelihood of outcomes. As such, this approach is clinically more useful than simple pairwise comparison of treatments and can provide a deeper understanding of the relative effectiveness and safety of strategies utilized in patients with STEMI even though some of these have not been directly compared in existing trials. We examined the heterogeneity among trials for each outcome using the multivariate R statistic.[20](#jah35065-bib-0020){ref-type="ref"}

We also estimated the probability that each treatment strategy was associated with maximum risk for each of the individual outcomes of death, myocardial reinfarction, stroke, or major bleeding under a Bayesian model with flat priors.

As many of the trials included subsequent reports with longer follow‐up times, we performed a sensitivity analysis by repeating our primary analysis using outcomes reported at longest reported follow‐up. In order to assess the impact of the thrombolysis to PCI interval time threshold on our study results, we performed another sensitivity analysis in which we used a thrombolysis to PCI interval threshold of 180 minutes (instead of 120 minutes) to define facilitated PCI (\<180 minutes) versus a pharmacoinvasive approach (≥180 minutes).

Finally, given their potential influence on study findings, we performed sensitivity analyses excluding the 2 largest trials (STREAM \[Strategic Reperfusion Early After Myocardial Infarction\][14](#jah35065-bib-0014){ref-type="ref"} and ASSENT‐4 \[Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention\][4](#jah35065-bib-0004){ref-type="ref"}) one at a time in order to assess their impact on study results.

Role of the Funding Source {#jah35065-sec-0013}
--------------------------

No sponsor of any of the individual trials had any role in the study design, data collection, data interpretation, drafting, or review of the report.

Results {#jah35065-sec-0014}
=======

We screened the titles and abstracts of 1767 potentially eligible reports, reviewed the full text of 64 articles reporting on 38 separate trials, and identified 31 trials that met our inclusion criteria (Figure [1](#jah35065-fig-0001){ref-type="fig"}). The characteristics of the included trials are outlined in Table [1](#jah35065-tbl-0001){ref-type="table"},[21](#jah35065-bib-0021){ref-type="ref"}, [22](#jah35065-bib-0022){ref-type="ref"}, [23](#jah35065-bib-0023){ref-type="ref"}, [24](#jah35065-bib-0024){ref-type="ref"}, [25](#jah35065-bib-0025){ref-type="ref"}, [26](#jah35065-bib-0026){ref-type="ref"}, [27](#jah35065-bib-0027){ref-type="ref"}, [28](#jah35065-bib-0028){ref-type="ref"}, [29](#jah35065-bib-0029){ref-type="ref"}, [30](#jah35065-bib-0030){ref-type="ref"}, [31](#jah35065-bib-0031){ref-type="ref"}, [32](#jah35065-bib-0032){ref-type="ref"}, [33](#jah35065-bib-0033){ref-type="ref"}, [34](#jah35065-bib-0034){ref-type="ref"}, [35](#jah35065-bib-0035){ref-type="ref"}, [36](#jah35065-bib-0036){ref-type="ref"}, [37](#jah35065-bib-0037){ref-type="ref"} and Figure [2](#jah35065-fig-0002){ref-type="fig"} shows the evidence network constructed from the 31 trials. A total of 15 357 patients were randomized in the included trials: 4212 to fibrinolytic therapy, 6139 to primary PCI, 2190 to a pharmacoinvasive approach, and 2816 to facilitated PCI. Among trials that included an arm with routine early PCI after fibrinolytic therapy, the weighted median time interval between administration of fibrinolytics to PCI was 90 minutes for facilitated PCI and 234 minutes for a pharmacoinvasive approach.

![Study selection.\
PCI indicates percutaneous coronary intervention.](JAH3-9-e015186-g001){#jah35065-fig-0001}

###### 

Characteristics of Included Studies

  Source (Publication Year)                                      No. of Subjects    Treatment              Fibrinolysis to PCI Interval, min   Short‐Term Follow‐Up, d   Death   Myocardial Reinfarction   Stroke   Major Bleeding
  -------------------------------------------------------------- ------------------ ---------------------- ----------------------------------- ------------------------- ------- ------------------------- -------- ----------------
  PRAGUE[7](#jah35065-bib-0007){ref-type="ref"} (2000)           99                 Fibrinolytic therapy   ···                                 30                        14      10                        1        N/A
  101                                                            Primary PCI        ···                    7                                   1                         0                                          
  100                                                            Facilitated PCI    68                     12                                  7                         3                                          
  STOPAMI[21](#jah35065-bib-0021){ref-type="ref"} (2000)         69                 Fibrinolytic therapy   ···                                 30                        5       4                         0        2
  71                                                             Primary PCI        ···                    3                                   2                         0       3                                  
  STAT[22](#jah35065-bib-0022){ref-type="ref"} (2001)            61                 Fibrinolytic therapy   ···                                 42                        2       8                         2        7
  62                                                             Primary PCI        ···                    3                                   3                         1       4                                  
  STOPAMI‐2[23](#jah35065-bib-0023){ref-type="ref"} (2002)       81                 Fibrinolytic therapy   ···                                 30                        5       4                         1        1
  81                                                             Primary PCI        ···                    2                                   0                         1       1                                  
  C‐PORT[24](#jah35065-bib-0024){ref-type="ref"} (2002)          226                Fibrinolytic therapy   ···                                 42                        16      20                        8        15
  225                                                            Primary PCI        ···                    12                                  11                        3       29                                 
  Zwolle[25](#jah35065-bib-0025){ref-type="ref"} (2002)          41                 Fibrinolytic therapy   ···                                 30                        9       6                         3        3
  46                                                             Primary PCI        ···                    3                                   1                         1       5                                  
  CAPTIM[26](#jah35065-bib-0026){ref-type="ref"} (2002)          419                Fibrinolytic therapy   ···                                 30                        16      15                        4        2
  421                                                            Primary PCI        ···                    20                                  7                         0       8                                  
  SIAM‐III[10](#jah35065-bib-0010){ref-type="ref"} (2003)        81                 Fibrinolytic therapy   ···                                 30                        8       2                         2        6
  82                                                             Pharmacoinvasive   210                    4                                   2                         1       8                                  
  DANAMI‐2[27](#jah35065-bib-0027){ref-type="ref"} (2003)        782                Fibrinolytic therapy   ···                                 30                        61      49                        16       N/A
  790                                                            Primary PCI        ···                    52                                  13                        9                                          
  PRAGUE‐2[28](#jah35065-bib-0028){ref-type="ref"} (2003)        421                Fibrinolytic therapy   ···                                 30                        42      13                        9        N/A
  429                                                            Primary PCI        ···                    29                                  6                         1                                          
  BRAVE[16](#jah35065-bib-0016){ref-type="ref"} (2004)           128                Primary PCI            ···                                 30                        2       1                         0        2
  125                                                            Pharmacoinvasive   125                    2                                   2                         1       7                                  
  GRACIA‐1[9](#jah35065-bib-0009){ref-type="ref"} (2004)         251                Fibrinolytic therapy   ···                                 30                        6       4                         1        4
  248                                                            Pharmacoinvasive   1002                   6                                   3                         0       4                                  
  APAMIT[29](#jah35065-bib-0029){ref-type="ref"} (2004)          36                 Primary PCI            ···                                 30                        1       1                         1        2
  34                                                             Facilitated PCI    60                     1                                   0                         0       1                                  
  CAPITAL AMI[30](#jah35065-bib-0030){ref-type="ref"} (2005)     84                 Fibrinolytic therapy   ···                                 30                        3       11                        1        6
  86                                                             Facilitated PCI    90                     2                                   4                         1       7                                  
  Leipzig[31](#jah35065-bib-0031){ref-type="ref"} (2005)         82                 Fibrinolytic therapy   ···                                 30                        4       7                         1        5
  82                                                             Facilitated PCI    84                     2                                   3                         0       4                                  
  ADVANCE MI[5](#jah35065-bib-0005){ref-type="ref"} (2005)       77                 Primary PCI            ···                                 30                        0       2                         N/A      8
  69                                                             Facilitated PCI    84                     5                                   1                         17                                         
  ASSENT‐4[4](#jah35065-bib-0004){ref-type="ref"} (2006)         838                Primary PCI            ···                                 90                        41      30                        1        37
  829                                                            Facilitated PCI    104                    55                                  49                        22      46                                 
  WEST[8](#jah35065-bib-0008){ref-type="ref"} (2006)             100                Fibrinolytic therapy   ···                                 30                        4       9                         0        1
  100                                                            Primary PCI        ···                    1                                   3                         1       1                                  
  104                                                            Pharmacoinvasive   295                    1                                   6                         1       2                                  
  SWEDES[32](#jah35065-bib-0032){ref-type="ref"} (2006)          104                Fibrinolytic therapy   ···                                 30                        4       2                         3        N/A
  101                                                            Primary PCI        ···                    3                                   0                         0                                          
  HIS[33](#jah35065-bib-0033){ref-type="ref"} (2006)             23                 Fibrinolytic therapy   ···                                 30                        3       1                         0        N/A
  25                                                             Primary PCI        ···                    1                                   0                         0                                          
  Bialystok[34](#jah35065-bib-0034){ref-type="ref"} (2007)       200                Fibrinolytic therapy   ···                                 30                        18      11                        3        4
  201                                                            Primary PCI        ···                    10                                  5                         1       4                                  
  GRACIA‐2[15](#jah35065-bib-0015){ref-type="ref"} (2007)        108                Primary PCI            ···                                 30                        5       1                         0        3
  104                                                            Pharmacoinvasive   276                    3                                   1                         1       2                                  
  CARESS‐in‐AMI[13](#jah35065-bib-0013){ref-type="ref"} (2008)   300                Fibrinolytic therapy   ···                                 30                        14      6                         4        7
  298                                                            Pharmacoinvasive   135                    9                                   4                         2       10                                 
  ATAMI[35](#jah35065-bib-0035){ref-type="ref"} (2008)           162                Primary PCI            ···                                 30                        9       3                         1        0
  151                                                            Facilitated PCI    92                     1                                   2                         0       0                                  
  FINESSE[3](#jah35065-bib-0003){ref-type="ref"} (2008)          806                Primary PCI            ···                                 90                        36      15                        8        21
  828                                                            Facilitated PCI    90                     43                                  17                        9       39                                 
  TRANSFER‐AMI[11](#jah35065-bib-0011){ref-type="ref"} (2009)    522                Fibrinolytic therapy   ···                                 30                        18      30                        6        47
  537                                                            Pharmacoinvasive   234                    24                                  18                        3       40                                 
  NORDISTEMI[12](#jah35065-bib-0012){ref-type="ref"} (2010)      132                Fibrinolytic therapy   ···                                 30                        3       7                         5        3
  134                                                            Pharmacoinvasive   163                    3                                   2                         3       2                                  
  TRIANA[36](#jah35065-bib-0036){ref-type="ref"} (2011)          134                Fibrinolytic therapy   ···                                 30                        23      11                        4        6
  132                                                            Primary PCI        ···                    18                                  7                         1       5                                  
  LIPSIA‐STEMI[6](#jah35065-bib-0006){ref-type="ref"} (2011)     78                 Primary PCI            ···                                 30                        4       4                         1        2
  80                                                             Facilitated PCI    85                     5                                   5                         1       2                                  
  STREAM[14](#jah35065-bib-0014){ref-type="ref"} (2013)          948                Primary PCI            ···                                 30                        42      21                        5        45
  944                                                            Pharmacoinvasive   483                    43                                  23                        15      61                                 
  EARLY‐MYO[37](#jah35065-bib-0037){ref-type="ref"} (2017)       173                Primary PCI            ···                                 30                        2       1                         0        0
  171                                                            Pharmacoinvasive   464                    1                                   1                         0       1                                  

ASSENT‐4 indicates Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention; ATAMI, Alteplase and Tirofiban in Acute Myocardial Infarction; BRAVE, Bavarian Reperfusion Alternatives Evaluation; CAPTIM, Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction; CARESS‐in‐AMI, Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction; C‐PORT, Atlantic Cardiovascular Patient Outcomes Research Team; DANAMI‐2, Danish Trial in Acute Myocardial Infarction‐2; EARLY‐MYO, Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST‐Segment‐Elevation Myocardial Infarction; FINESSE, Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events; GRACIA, Grupo de Análisis de la Cardiopatía Isquémica Aguda; LIPSIA‐STEMI, Leipzig Immediate Prehospital Facilitated Angioplasty in ST‐Segment Myocardial Infarction; NORDISTEMI, Norwegian Study on District Treatment of ST‐Elevation Myocardial Infarction; PCI, percutaneous coronary intervention; PRAGUE, Primary Angioplasty in Patients Transferred From General Community Hospitals to Specialized PTCA Units With or Without Emergency Thrombolysis; SIAM‐III, Southwest German Interventional Study in Acute Myocardial Infarction; STOPAMI, Stent Versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction; STREAM, Strategic Reperfusion Early after Myocardial Infarction; TRANSFER‐AMI, Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction; TRIANA, Tratamiento del Infarto Agudo de Miocardio en Ancianos; and WEST, Which Early ST‐Elevation Myocardial Infarction Therapy.

![Evidence network for trials included in the meta‐analysis.\
The WEST (Which Early ST‐Elevation Myocardial Infarction Therapy)[8](#jah35065-bib-0008){ref-type="ref"} and PRAGUE (Primary Angioplasty in Patients Transferred From General Community Hospitals to Specialized PTCA Units With or Without Emergency Thrombolysis)[7](#jah35065-bib-0007){ref-type="ref"}, [28](#jah35065-bib-0028){ref-type="ref"} trials each included 3 treatment arms, which is the reason the tally of studies in the diagram is 34 rather than 30 (which was the total number of studies in our analysis). PCI indicates percutaneous coronary intervention.](JAH3-9-e015186-g002){#jah35065-fig-0002}

Unadjusted Mortality {#jah35065-sec-0015}
--------------------

All 31 trials provided information on the end point of death, with a median follow‐up period of 30 days. An examination of unadjusted mortality revealed that 806 patients in the included studies died: 278 patients randomized to fibrinolytic therapy (median 6.2%, range 2.3--22.0%; interquartile range \[IQR\], 3.8--9.9%), 306 (5.0%) patients randomized to primary PCI (median 4.7%, range 0.0--13.6%; IQR, 2.9--5.4%), 96 (3.5%) patients randomized to a pharmacoinvasive approach (median 2.7%, range 0.6--4.9%; IQR, 1.8--4.1%), and 126 (5.6%) patients randomized to facilitated PCI (median 5.2%, range 0.7--12.0%; IQR, 2.4--6.6%).

Nonfatal Reinfarction {#jah35065-sec-0016}
---------------------

All 31 trials also provided information on the end point of nonfatal reinfarction, with a median follow‐up of 30 days. In unadjusted analyses, a total of 516 patients experienced nonfatal myocardial reinfarction: 230 (5.5%) patients randomized to fibrinolytic therapy (median 5.7%, range 1.6--14.6%; IQR, 3.6--8.8%), 137 (2.2%) patients randomized to primary PCI (median 2.0%, range 0.0--5.3%; IQR, 1.0--2.9%), 61 (2.8%) patients randomized to a pharmacoinvasive approach (median 1.4%, range 0.6--5.8%; IQR, 1.0--2.4%), and 88 (3.1%) patients randomized to facilitated PCI (median 3.7%, range 0.0--7.0%; IQR, 1.4--5.9%).

Stroke {#jah35065-sec-0017}
------

We found that 30 trials provided data on stroke, with a median follow‐up period of 30 days. In unadjusted analyses, a total of 173 patients experienced a stroke: 74 (1.8%) patients randomized to fibrinolytic therapy (median 1.3%, range 0.0--7.3%; IQR, 1.0--2.9%), 36 (0.6%) patients randomized to primary PCI (median 0.5%, range 0.0--2.8%; IQR, 0.0--1.2%), 27 (1.0%) patients randomized to a pharmacoinvasive approach (median 0.9%, range 0.0--2.2%; IQR, 0.6--1.2%), and 36 (1.6%) patients randomized to facilitated PCI (median 1.1%, range 0.0--1.6%; IQR, 0.0--1.6%).

Major Bleeding {#jah35065-sec-0018}
--------------

A total of 26 trials contributed to the end point of major bleeding, with a median follow‐up of 30 days. In unadjusted analyses, 552 patients developed a major bleeding complication: 119 (4.3%) patients randomized to fibrinolytic therapy (median 3.7%, range 0.5--11.5%; IQR, 1.9--7.2%), 180 (3.8%) patients randomized to primary PCI (median 2.8%, range 0.3--12.9%; IQR, 1.7--5.2%), 137 (4.9%) patients randomized to a pharmacoinvasive approach (median 2.6%, range 0.6--9.8%; IQR, 1.7--6.2%), and 116 (5.4%) patients randomized to facilitated PCI (median 4.8%, range 0.3--24.6%; IQR, 2.8--6.2%).

Multivariate Network Meta‐Analysis Results {#jah35065-sec-0019}
------------------------------------------

The results of the multivariate network meta‐analysis are listed in Table [2](#jah35065-tbl-0002){ref-type="table"}. Among the 4 strategies evaluated, primary PCI was associated with the lowest odds of death (odds ratio \[OR\], 0.73; 95% CI, 0.61--0.89) and nonfatal reinfarction (OR, 0.38; 95% CI, 0.29--0.50), as well as the lowest odds of stroke (OR, 0.38; 95% CI, 0.24--0.60). Among the remaining strategies, the pharmacoinvasive approach was associated with the lowest odds of mortality (OR, 0.79; 95% CI, 0.59--1.08). There was no statistically significant difference in the risk of major bleeding among the strategies evaluated; however, there was a trend for higher odds of major bleeding with facilitated PCI (OR, 1.51; 95% CI, 0.93--2.46). The multivariate R statistic calculated for each of the 4 outcomes revealed no evidence of significant heterogeneity among the trials (Table [2](#jah35065-tbl-0002){ref-type="table"}). The Bayesian model indicated that the probability of being the worst of the 4 treatment strategies was highest for fibrinolytic therapy and lowest for primary PCI in regards to the risk of death, nonfatal reinfarction, and stroke (Table [3](#jah35065-tbl-0003){ref-type="table"}).

###### 

Multivariate Network Meta‐Analysis Results

  Outcome          Fibrinolytic Therapy   Primary PCI         Pharmacoinvasive Approach   Faciliated PCI      Multivariate R Statistic   No. of Trials                      
  ---------------- ---------------------- ------------------- --------------------------- ------------------- -------------------------- ------------------- ------- ------ ----
  Death            Reference              0.73 (0.61--0.89)   0.002                       0.79 (0.59--1.08)   0.14                       0.90 (0.66--1.24)   0.53    1.00   31
  Reinfarction     Reference              0.38 (0.29--0.50)   \<0.001                     0.53 (0.37--0.75)   \<0.001                    0.52 (0.36--0.76)   0.001   1.00   31
  Stroke           Reference              0.38 (0.24--0.60)   \<0.001                     0.70 (0.38--1.29)   0.25                       0.71 (0.33--1.53)   0.38    1.00   30
  Major bleeding   Reference              1.03 (0.72--1.49)   0.86                        1.19 (0.81--1.74)   0.36                       1.51 (0.93--2.46)   0.10    1.28   25

OR indicates odds ratio; and PCI, percutaneous coronary intervention.

###### 

Results of the Bayesian Model to Estimate Probability of Maximum Risk

  Outcome          Fibrinolytic Therapy, %   Primary PCI   Pharmacoinvasive Approach, %   Facilitated PCI, %   No. of Trials
  ---------------- ------------------------- ------------- ------------------------------ -------------------- ---------------
  Death            69.8                      0.0%          6.0                            24.2                 31
  Reinfarction     99.9                      0.0%          0.1                            0.0                  31
  Stroke           72.6                      0.0%          11.1                           16.3                 29
  Major bleeding   1.7                       1.1%          19.8                           77.4                 26

These results estimate the probability that each treatment approach is associated with maximum risk of each adverse outcome relative to the other treatments. For example, these results suggest that there is a 69.8% probability that fibrinolytic therapy is associated with the highest risk of death as compared with the other 3 strategies. They also indicate that facilitated percutaneous coronary intervention (PCI) has the second highest probability (24.2%) of being associated with the highest mortality risk among the compared strategies and primary PCI has a \>99.9% probability of having the lowest mortality risk among the treatments.

Furthermore, the results of the Bayesian model suggested that the efficacy and safety of a pharmacoinvasive approach is superior to facilitated PCI when compared head‐to‐head. For example, the overall probability of facilitated PCI having the highest mortality rate among the compared treatments was estimated at 24.2% (second only to fibrinolytic therapy at 69.8%) and only 6.0% for a pharmacoinvasive approach. The probability of having the highest rates of stroke and major bleeding were also higher for facilitated PCI as compared with a pharmacoinvasive approach (16.3% versus 11.1%, and 77.4% versus 19.8%, respectively).

The results of the sensitivity analysis using the longest published follow‐up of included studies revealed no significant difference from the primary analysis using short‐term follow‐up (Tables [S2](#jah35065-sup-0001){ref-type="supplementary-material"} and [S3](#jah35065-sup-0001){ref-type="supplementary-material"}). In the sensitivity analysis in which a thrombolysis to PCI time interval of 180 minutes was used as the threshold to define facilitated PCI versus a pharmacoinvasive approach, the treatment arms of 3 trials----BRAVE (Bavarian Reperfusion Alternatives Evaluation),[16](#jah35065-bib-0016){ref-type="ref"} CARESS‐in‐AMI (Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction),[13](#jah35065-bib-0013){ref-type="ref"} and NORDISTEMI (Norwegian Study on District Treatment of ST‐Elevation Myocardial Infarction)[12](#jah35065-bib-0012){ref-type="ref"}----were recategorized from a pharmacoinvasive approach to facilitated PCI. This resulted in a slightly higher stroke risk for pharmacoinvasive approach compared with facilitated PCI in the Bayesian analysis but no other significant changes in our findings (Tables [S4](#jah35065-sup-0001){ref-type="supplementary-material"} and [S5](#jah35065-sup-0001){ref-type="supplementary-material"}). Sensitivity analyses excluding the ASSENT‐4 and STREAM trials from the analysis revealed no significant impact on the study findings (Tables [S6](#jah35065-sup-0001){ref-type="supplementary-material"} through [S9](#jah35065-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah35065-sec-0020}
==========

Our study adds to the substantial body of evidence indicating that during STEMI, primary PCI, when performed in a timely manner, is the best strategy for reducing short‐term major adverse cardiac events, including death. The key novel insights provided by our study, however, pertain to situations where timely primary PCI is not possible---scenarios in which the best approach to treatment of STEMI remains unclear and controversial. Our findings suggest that fibrinolysis followed by routine early invasive therapy is more effective in this setting as compared with standard fibrinolytic therapy alone. Importantly, our study also suggests that the time interval between fibrinolysis and PCI is a key determinant of the efficacy and safety of any approach combining fibrinolysis with routine early invasive therapy.

A key advantage of our study is that it incorporates data from trials involving all 4 reperfusion strategies that are currently utilized in contemporary practice, synthesizing them in a manner that allows for comparison and ranking. A single model leverages both direct and indirect comparisons between reperfusion strategies, which is useful for clinicians taking care of these patients as well as policy makers who design STEMI systems of care. This approach also allowed us to directly examine heterogeneity among trials in the time interval between fibrinolysis and PCI in those studies that examined routine early invasive therapy following fibrinolysis. For this issue, our results suggest that when the time interval between fibrinolysis and PCI is \<2 hours (facilitated PCI), there is an increased risk of major bleeding and possibly death as compared with when the interval is 2 to 24 hours (pharmacoinvasive approach).

These findings have implications for a large number of patients worldwide. It is estimated that over 7 million people die annually from acute myocardial infarction and this number is projected to increase to over 9 million by 2030.[38](#jah35065-bib-0038){ref-type="ref"} Approximately 80% of these deaths occur in low‐ and middle‐income countries, where resources such as PCI‐capable hospitals are scarce.[38](#jah35065-bib-0038){ref-type="ref"} Fibrinolytic therapy remains the most widely used reperfusion strategy in the world.[39](#jah35065-bib-0039){ref-type="ref"} In many developing countries, cardiac catheterization laboratories are only available in larger cities, making the use of primary PCI impossible for a large proportion of the population. A pharmacoinvasive approach is an attractive option in this setting as it expands access to PCI once patients are stabilized. Even in the United States, it is estimated that as many as 20% of individuals live more than 60 minutes away from a PCI‐capable hospital,[40](#jah35065-bib-0040){ref-type="ref"}, [41](#jah35065-bib-0041){ref-type="ref"} and recent increases in PCI capacity among hospitals has mostly occurred in areas where neighboring facilities already have this capability rather than in areas of new geographic coverage.[42](#jah35065-bib-0042){ref-type="ref"} These facts highlight the crucial importance of understanding the potential role of alternative reperfusion strategies to primary PCI for treating STEMI.

It is important to note that PCI‐related delays in trials included in our study were relatively short: median randomization to balloon time in the primary PCI arms of the included trials was 80 minutes (IQR, 76--105 minutes) overall and 77 minutes (IQR, 76--80 minutes) for trials that compared primary PCI with a pharmacoinvasive approach. In other words, the strategy of primary PCI studied in trials included in our meta‐analysis was ideally delivered without prolonged delays beyond guideline recommendations. In a recent post hoc analysis of the STREAM trial it was shown that the longer the delay to revascularization with primary PCI, the more favorably the pharmacoinvasive approach compared with it.[43](#jah35065-bib-0043){ref-type="ref"} Thus, the pharmacoinvasive approach may be an even more attractive option than our results suggest in real‐world settings where delays may be more prolonged.

Study Limitations {#jah35065-sec-0021}
=================

Our study should be interpreted in the context of the following limitations. First, there are potential sources of heterogeneity between studies that need to be considered. However, formal evaluation of heterogeneity using the multivariate R did not reveal evidence of significant heterogeneity in our analyses, suggesting that our results are reasonably robust. Second, as with any meta‐analysis, we were limited by the quality of the data collected at the level of the individual study. Finally, the limited number of studies between a few of the key reperfusion strategies (eg, no studies compared pharmacoinvasive therapy with facilitated PCI) limited the evidence available from direct comparisons. That said, it is unlikely that such studies will be performed, which makes the explicit comparisons we performed through this meta‐analysis even more valuable.

Conclusions {#jah35065-sec-0022}
===========

Primary PCI is the preferred treatment for STEMI. Our findings suggest that when primary PCI is unavailable as a reperfusion therapy, a pharmacoinvasive approach is superior to facilitated PCI or standard fibrinolytic therapy in terms of mortality, stroke, and major bleeding. This information will help guide better design of STEMI systems of care across diverse healthcare systems for this important disease condition.
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